Sugar Land, Texas, United States The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Sugar Land.
The fund is constantly included in less than 2 deals per year. The usual things for fund are deals in the range of more than 100 millions dollars. The high activity for fund was in 2015. The increased amount of exits for fund were in 2015.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - Austria. Among the various public portfolio startups of the fund, we may underline Nabriva Therapeutics We can highlight the next thriving fund investment areas, such as Health Care, Biotechnology. Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund.
The usual cause for the fund is to invest in rounds with 9 partakers. Despite the GLS Ventures, startups are often financed by Arax Capital Partners. The meaningful sponsors for the fund in investment in the same round are Wellcome Trust, Vivo Capital, Phase4 Partners.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Avista Development | Spokane, United States, Washington |
| car2go | Israel, Tel Aviv, Tel Aviv District |
| China State-Owned Capital Venture Investment Fund | Beijing, Beijing, China |
| Fuqua Investments | - |
| Guillemot Corporation | Bretagne, Chantepie, France |
| Huaxin Ziyuan | China, Guangdong, Shenzhen |
| Jaguar Land Rover Tech Incubator | Oregon, Portland, United States |
| Liga Ventures | Brazil, São Paulo, Sao Paulo |
| NICE Group | Seoul, Seoul-t'ukpyolsi, South Korea |
| SODIV ALSACE | Alsace, France, Grand Est |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Nabriva Therapeutics | $120M | 07 Apr 2015 | Vienna |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Nabriva Therapeutics | $120M | 07 Apr 2015 | Vienna |
